References
- June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
- Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex genome-edited T-cell manufacturing platform for “Off-the-Shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853–3864.
- Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9:374.
- Gautron AS, Juillerat A, Guyot V, et al. Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy. Mol Ther Nucleic Acids. 2017;9:312–321.
- Qasim W, Amrolia PJ, Samarasinghe S, et al. First clinical application of talen Engineered Universal CAR19 T cells in B-ALL. Blood. 2015;126:2046.
- Guzman ML, Sugita M, Zong H, et al. Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 prolong overall survival of AML patient-derived Xenografts. Blood. 2016;128:765.
- Cellectis reports clinical hold of UCART123 studies [Internet]. New York (N.Y.): Cellectis; 2017 [cited 2017 Sep 04. Available from: http://www.cellectis.com/en/press/cellectis-reports-clinical-hold-of-ucart123-studies/
- FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN [Internet]. New York (N.Y.): Cellectis; 2017 [cited 2017 Nov 06]. Available from: http://www.cellectis.com/en/press/fda-lifts-clinical-hold-on-cellectis-phase-1-clinical-trials-with-ucart123-in-aml-and-bpdcn/
- Georgiadis C, Qasim W. Emerging applications of gene edited T cells for the treatment of leukemia. Expert Rev Hematol. 2017;10(9):753–755.
- Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013;31(9):827–832.
- Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184–191.
- Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33(2):187–197.
- Kim D, Bae S, Park J, et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods. 2015;12(3):237–243.
- Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8(10):17002–17011.